Medicines Used in Heart Failure: Drug Classes and Their Roles

Heart failure is a clinical condition in which the heart is unable to pump blood adequately to meet the body's needs. It can occur because of different underlying cardiovascular conditions, and treatment depends on the type and severity of heart failure, associated diseases, symptoms, and individual patient factors.

Several groups of medicines may be used in the management of heart failure. Their roles are different: some improve long-term outcomes, some reduce fluid overload and symptoms, and others are used in specific clinical situations.

This article provides an educational overview of important medicine classes used in heart failure.

Major Drug Classes Used in Heart Failure

Commonly discussed medicine classes include:

• Diuretics
• Mineralocorticoid receptor antagonists
• Beta-blockers
• Renin-angiotensin system–acting medicines
• Angiotensin receptor-neprilysin inhibitors
• Sodium-glucose cotransporter-2 inhibitors
• Selected vasodilator therapies
• Positive inotropic medicines in specific acute or advanced situations

The appropriate combination depends on the patient's type of heart failure and clinical condition.

1. Diuretics

Diuretics help the kidneys remove excess sodium and water from the body. They are particularly useful when heart failure causes fluid retention, peripheral edema, or pulmonary congestion.

Loop Diuretics

Examples include:

• Furosemide
• Bumetanide
• Torsemide

Loop diuretics are commonly used when significant fluid overload is present. They can provide relatively rapid relief of congestion.

Important monitoring considerations include fluid balance, blood pressure, kidney function, and electrolyte concentrations.

Thiazide and Thiazide-Like Diuretics

Examples include:

• Hydrochlorothiazide
• Metolazone

These medicines may be used in selected patients. In some situations, a thiazide-type diuretic may be combined with a loop diuretic when additional diuresis is required, but this requires careful clinical monitoring.

2. Mineralocorticoid Receptor Antagonists

Mineralocorticoid receptor antagonists reduce the effects of aldosterone.

Examples include:

• Spironolactone
• Eplerenone

These medicines can have an important role in selected patients with heart failure, particularly certain patients with reduced ejection fraction.

Because they can increase potassium levels and affect kidney function, appropriate monitoring is important.

3. Beta-Blockers

Certain beta-blockers have an established role in the long-term treatment of selected patients with heart failure with reduced ejection fraction.

Examples include:

• Carvedilol
• Metoprolol succinate
• Bisoprolol

Beta-blockers can reduce harmful effects of persistent sympathetic nervous system activation on the heart.

They are generally introduced and adjusted carefully in clinically stable patients because excessive slowing of the heart rate or a sudden reduction in cardiac function can cause problems.

Important: Not every beta-blocker has the same evidence or indication in heart failure. The specific medicine and formulation matter.

4. Renin-Angiotensin System Inhibitors

The renin-angiotensin system contributes to blood-vessel constriction and fluid retention.

Medicines that interfere with this system include:

• ACE inhibitors
• Angiotensin II receptor blockers (ARBs)
• Other renin-angiotensin system therapies

Examples of ACE inhibitors include medicines such as enalapril and lisinopril. Examples of ARBs include losartan and valsartan.

These medicines may reduce the effects of excessive neurohormonal activation and are important components of therapy for appropriate patients.

Kidney function and potassium levels should be monitored when clinically indicated.

5. Angiotensin Receptor-Neprilysin Inhibitor

An angiotensin receptor-neprilysin inhibitor (ARNI) combines two pharmacological actions.

Sacubitril/valsartan is an important example.

This therapy can be used in appropriate patients with certain forms of heart failure, particularly heart failure with reduced ejection fraction.

Because it affects blood pressure and kidney-related parameters and can influence potassium levels, clinical monitoring is required.

6. Sodium-Glucose Cotransporter-2 Inhibitors

Sodium-glucose cotransporter-2 (SGLT2) inhibitors were originally developed for diabetes management but are also important in the treatment of certain patients with heart failure.

Examples include:

• Dapagliflozin
• Empagliflozin

Their benefits in heart failure extend beyond glucose lowering. They can reduce the risk of certain heart-failure-related clinical outcomes in appropriate patients.

Their use depends on the patient's clinical circumstances and the specific indication.

7. Vasodilator Therapy

Some medicines reduce vascular resistance and alter the workload placed on the heart.

For selected patients, particularly when other therapies cannot be used or when specific clinical indications exist, combinations such as hydralazine and isosorbide dinitrate may be considered.

The suitability of this treatment depends on the patient's clinical characteristics and current treatment plan.

8. Positive Inotropic Medicines

Positive inotropic medicines increase the force of cardiac contraction.

Historically and pharmacologically important examples include:

• Digoxin
• Dobutamine
• Milrinone

Digoxin

Digoxin is a cardiac glycoside that can increase cardiac contractility and influence conduction through the atrioventricular node.

It may have a role in selected patients, but it requires careful consideration because its therapeutic range is relatively narrow and toxicity can occur.

Dobutamine

Dobutamine is an intravenous positive inotropic medicine used mainly in specific acute-care situations where increased cardiac output is required.

It is not generally used as routine long-term oral therapy for chronic heart failure.

Milrinone

Milrinone is a phosphodiesterase-3 inhibitor with positive inotropic and vasodilator effects.

Like dobutamine, it is generally associated with specialized acute or advanced heart-failure management rather than routine treatment of stable chronic heart failure.

Why Drug Selection Is Individualized

Heart failure is not a single uniform disease. Treatment can differ according to:

• Ejection fraction
• Symptoms and severity
• Blood pressure
• Kidney function
• Electrolyte levels
• Heart rhythm
• Other cardiovascular diseases
• Diabetes and other comorbidities
• Current medicines
• Previous treatment response
• Acute versus chronic clinical status

Therefore, a list of medicines should not be interpreted as a recommendation for self-treatment.

Monitoring During Heart Failure Treatment

Depending on the medicines being used, healthcare professionals may monitor:

• Blood pressure
• Heart rate
• Kidney function
• Serum potassium
• Other electrolytes
• Fluid status
• Body weight
• Symptoms and exercise tolerance
• Heart rhythm when clinically indicated

Monitoring helps identify treatment-related problems and determine whether therapy needs adjustment.

Key Points for Pharmacy Students

• Diuretics are particularly useful for controlling congestion and fluid retention.
• Certain beta-blockers have important roles in chronic heart failure management.
• Mineralocorticoid receptor antagonists can provide important benefits in appropriate patients.
• Renin-angiotensin system therapies